Evidence map›Paper›PMID 30288045›Full record

ArticleTherapeutics and clinical risk management2018

Changes in cardiovascular risk and clinical outcomes in a HIV/AIDS cohort study over a 1-year period at a specialized clinic in Mexico.

Angelica Cibrián-Ponce, Miguel A Sánchez-Alemán, Sara García-Jiménez, Eduardo Pérez-Martínez, Germán Bernal-Fernández, Miguel Castañon-Mayo, Laura Ávila-Jiménez, Cairo D Toledano-Jaimes

Abstract read
In one paragraph

Article in Therapeutics and clinical risk management, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Angelica Cibrián-PonceFaculty of Pharmacy, University of Morelos, Cuernavaca, Morelos, Mexico, tjcd_ff@uaem.mx.
Miguel A Sánchez-AlemánCenter for Infectious Diseases Research, National Institute of Public Health, Cuernavaca, Morelos, Mexico.
Sara García-JiménezFaculty of Pharmacy, University of Morelos, Cuernavaca, Morelos, Mexico, tjcd_ff@uaem.mx.
Eduardo Pérez-MartínezRetrovirus Clinic, Regional General Hospital Number 1, Cuernavaca, Morelos, Mexico.
Germán Bernal-FernándezFaculty of Pharmacy, University of Morelos, Cuernavaca, Morelos, Mexico, tjcd_ff@uaem.mx.
Miguel Castañon-MayoNephrology Service, Regional General Hospital Number 1, Mexican Institute of Social Security, Morelos, Mexico.
Laura Ávila-JiménezHealth Research Morelos, Mexican Institute of Social Security, Morelos, Mexico.
Cairo D Toledano-JaimesFaculty of Pharmacy, University of Morelos, Cuernavaca, Morelos, Mexico, tjcd_ff@uaem.mx.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThe third report of the National Cholesterol Education Program guidelines recommends calculating the 10-year morbidity of atherosclerotic cardiovascular disease (ASCVD) using risk calculators when treating high blood cholesterol in adults. We analyzed the changes in cardiovascular risk (CVR) among Mexican patients with HIV. PATIENTS AND

methodsThis observational, prospective cohort study compared the CVR after 1 year of antiretroviral treatment among 460 HIV patients from a Mexican clinic. Changes using the ASCVD risk estimator and changes in clinical outcomes were analyzed. The results were categorized as low or high CVR using a cutoff of 7.5%.

resultsThe CVR initially had a median of 2.3% (interquartile range [IQR]: 1%-4.8%), which changed to 2.4% (IQR: 1.5%-5.5%) after 1 year (

conclusionMore than 50% of the population had an increase in CVR after 1 year. Of these patients, 4.3% changed from the low to high CVR group. Although the guidelines proposed different time periods for performing CVR estimations, this study showed that such assessments offered valuable clinical data over a relatively short-term period.

Indexed as

cardiovascular risk factorsHIVmetabolic syndrome

Identifiers

PMID30288045
PMCPMC6161730

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.